5 results
The primary objective is to characterize the programming effects of Boston Scientific Vercise* PC System using the Deep Brain Stimulation Directional Lead for bilateral subthalamic nucleus DBS for the treatment of Parkinson*s disease in acute and…
The primary objective of this trial is as follows:• To determine the pharmacokinetics of anidulafungin administered to obese patients with a BMI >= 40 kg/m2. The secondary objective of this trial is as follows:• To simulate pharmacokinetics…
The primary objective of this trial is as follows:• To determine the pharmacokinetics of anidulafungin given once in every 2 days (q48h) or once in every 3 days (q72h) to patients undergoing an allogeneic haematopoietic stem cell transplant…
To investigate the correlation of pharmacokinetic parameters of anidulafungin with markers for disease severity and plasma protein levels.
It is hypothesized that eRFA leads to increased stent patency, fewer re-interventions, fewer (permanent) external drains, and consequently increased quality of life. The primary aim of the proposed pilot study is to evaluate whether eRFA is feasible…